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Abstract 
We conducted a cost-effectiveness analysis of brentuximab vedotin for the treatment of 
relapsed and refractory Hodgkin Lymphoma (HL) from health care system perspective in 
Canada. We developed a Markov decision analytical model to simulate lifetime costs and 
benefits and parameterized the model using brentuximab phase II clinical trial and cd-link 
data which is a linked datasets of cancer registry with administrative databases of Ontario, 
Canada. In the base case scenario, brentuximab treatment led to an increase of 0.352 Quality 
Adjusted Life Years (QALYs) per person and $108,500 per person, which resulted in 
incremental cost effectiveness ratio (ICER) of $308,532 per QALYs gained. The ICER was 
sensitive to hazard ratio, cost per dose of brentuximab and utility values. In conclusion, 
brentuximab has an ICER higher than $100,000 per QALY threshold that is often classified 
as having “weak evidence for adoption and appropriate utilization” in Canada according best 
available information so far. The substantial reduction (e.g., 72%) in the cost of unit dose of 
brentuximab can reduce ICER dramatically and make the drug cost effective. 
Keywords 
Cost-effectiveness, Hodgkin Lymphoma, brentuximab, phase II trial, targeted therapy, 
Canada 
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Glossary of Terms 
Autologous Stem Cell Transplantation: A procedure in which blood-forming stem cells 
(cells from which all blood cells develop) are removed, stored, and later given back to the 
same person. 
Allogeneic Stem Cell Transplantation: A procedure in which a person receives blood-
forming stem cells (cells from which all blood cells develop) from a genetically similar, but 
not identical, donor. This is often a sister or brother, but could be an unrelated donor. 
Bulky Disease: Bulky disease describes an area of lymphoma that is greater than 10 cm 
(about 4 inches) in size or the disease takes up more than a third of the chest cavity at a 
generally accepted level of the spine (thoracic vertebrae 5-6) that is seen with a chest x-ray. 
Hematopoietic: pertaining to the formation of blood or blood cells. 
Hematological Malignancy: A cancer of the blood or bone marrow, such as leukemia or 
lymphoma. 
Karnofsky Performance Score (KPS): A standard way of measuring the ability of cancer 
patients to perform ordinary tasks. The Karnofsky performance scores range from 0 to 100. A 
higher score means the patient is better able to carry out daily activities. KPS may be used to 
determine a patient's prognosis, to measure changes in a patient’s ability to function, or to 
decide if a patient could be included in a clinical trial. 
Medical Technology: Healthcare products, interventions and procedures used to promote 
health, prevent, diagnose and treat disease. 
 xiii 
 
Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances 
in the body, including tumor cells. 
Neoplastic Cells: a cell that is part of tumor. 
Orphan Drug: A pharmaceutical agent intended to treat rare disease. 
Positive Predictive Value: The probability that a person with a positive test result has the 
disease. 
Risk Adapted Therapy: Treatment that is generally based on risk stratification. Risk 
depends on stage of disease, presence/absence of bulky disease and response to therapy. 
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Chapter 1  
1 Introduction 
        Hodgkin Lymphoma (HL) is a rare type of cancer with an annual rate of  3 per 
100,000 in Canada[1]. In 2010, 960 patients were diagnosed with HL and 116 patients 
died in Canada[1]. The conventional treatment options for HL include chemotherapy, 
radiotherapy and hematopoietic stem cell transplantation. Although survival outcomes for 
the majority of patients are promising, a significant proportion of the population cannot 
be cured with standard treatment regimens [2-4]. Management of disease after second 
line treatment becomes more difficult for medical specialists due to lack of guidelines 
and clinically strong studies.  
      Like in many cancer centers around the world, in Ontario cancer centers, the standard 
of care for second line treatment of HL is high dose chemotherapy plus autologous stem 
cell transplantation (ASCT). It has been shown that 50% of patients relapse after ASCT 
[5] and prognosis tends to be very poor with median survival less than one year for these 
patients [6, 7]. Currently, treating these patients remains a therapeutic challenge. The 
available treatment options are severely limited. Furthermore, these treatment options 
were tested in non-randomized setting and toxicity and treatment related mortality rates 
are higher, making them less attractive for the hematology community and patients.  
     The standard of care treatment options in the post-autologous SCT period include 
allogeneic stem cell transplantation, second ASCT, standard dose treatments and single 
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agents which are ultimately palliative. The reported survival benefits of these therapies 
are minimal with median survival in the range of 6 and 30 months [8-11]. In the last 
couple years, there have been attempts to develop new agents and new antibody 
therapeutic agents for the treatment of relapsed HL that resulted in minimal or no 
antitumor activity [12, 13]. 
     To gain entry into the market, pharmaceuticals are typically evaluated through a series 
of clinical trials beginning with phase I through to phase III randomized controlled trials 
that are required by regulatory bodies in order to get definitive results regarding the 
efficacy and safety of the new intervention. However, in the case of drugs thought to fill 
unmet medical need, results from phase II trials are considered sufficient evidence to 
obtain accelerated market approval with a condition that post marketing clinical trials 
must be conducted to verify the current clinical benefit. Health care payers decide 
whether or not to include these new and expensive therapies to drug formularies upon 
market approval. Thus, economic evaluation of such drugs at an early stage would yield 
interesting results to healthcare payers in light of the existing state of limited information. 
     Brentuximab vedotin (Adcetris), being an orphan drug, was granted accelerated 
approval recently from the FDA based on phase II trial results for the treatment of HL 
after ASCT or two prior multi agent chemotherapy regimen failures. Initial findings were 
promising and trial showed that objective response rate was 75% with a median 
progression free survival (PFS) of 5.6 months [14]. 
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     In this study we aim to evaluate cost-effectiveness of brentuximab from the Canadian 
healthcare payer perspective based on phase II trial results. We developed a decision 
analytic model and used cancer registry and administrative databases of Ontario to 
populate the model. This study has several objectives. First, we seek to establish the cost- 
effectiveness of brentuximab versus standard of care. Second we develop an “early look” 
model that will project lifetime costs and benefits. Finally, as Canadian pricing is not 
available, we determine the conditions under which brentuximab would be cost effective 
by conducting a threshold analysis. The remainder of the thesis is organized as follows: 
Chapter 2 summarizes literature review. Chapter 3 enumerates primary and secondary 
research questions. In chapter 4 we explain the materials and methods required to conduct 
cost-effectiveness analysis. We report the results in chapter 5 and conclude in chapters 6 
and 7. 
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Chapter 2  
2   Literature Review 
2.1 Hodgkin Lymphoma 
     Hodgkin’s disease is a cancer of the lymph tissue found in the lymphatic system 
which helps to fight against infectious diseases. The lymphatic system of the human body 
circulates lymph (fluid that carries white blood cells by means of lymph nodes and 
lymphatic vessels). There are hundreds of lymph nodes in the human body. The lymph 
nodes act as a filter and are clustered around certain parts of body such as the neck, 
underarm, chest, abdomen and groin. As lymph passes through, the lymph nodes filter 
out bacteria and unwanted cells including cancer cells. When a hematological malignancy 
occurs, the lymph nodes start to grow abnormally. These abnormal cells are called Reed-
Sternberg cells which are the markers of HL. Since the lymph nodes are spread 
throughout the body, cancer can initiate from anywhere inside the body. 
2.1.1 History and Disease Classification 
      This rare phenomenon was first explained by British doctor Thomas Hodgkin in 1832 
[15]. He described seven cases in his classic paper that forms the basis of HL disease to 
date. Two decades after Thomas Hodgkin described seven cases, numbers of additional 
cases with similar pathological traits were found. Subsequently, this disorder came to be 
known as Hodgkin disease [16]. Once the relationship of disease with lymphadenopathy 
(enlargement of lymph nodes) and the lymphatic system was revealed, it started to be 
known as HL [17]. 
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      Diagnosis of the disease is established by physical exam, blood tests, chest x-rays and 
biopsy. In general, patients diagnosed with HL may be treated by one or more of the 
following treatment options: chemotherapy, radiotherapy and stem cell transplantation. 
Selection of treatment depends on several factors such as patient characteristics and 
natural history of disease, e.g., cancer stage. In recent years, new treatment strategies 
have been developed and many more clinical trials across the globe are investigating 
variety of novel medical technologies that have potential to prevent and cure the HL [18].  
     According to a recent World Health Organization (WHO) classification of tumors, HL 
is divided into two sub-groups based on clinical, biologic and pathologic features: 
Classical Hodgkin Lymphoma (CHL) and Nodular Lymphocyte Predominant Hodgkin 
Lymphoma (NLPHL) [17]. Classical Hodgkin Lymphoma is further subdivided into four 
subtypes with distinctive clinical features: Nodular sclerosis, lymphocyte predominance, 
mixed cellularity and lymphocyte depleted [17, 19, 20]. NLPHL type is rare in practice 
and comprises only 5% of HL cases [21]. 
2.1.2 Natural History of Disease 
      The biological markers of CHL malignant cells are mononuclear or multinuclear 
large and abnormal cells known as Hodgkin Reed-Sternberg cells (HRS) or their variants 
[19]. The marker of NLPHL is lobulated nuclei cells known as lymphocytic and 
histiocytic (L&H; also known as popcorn cells) [19, 22]. B-cells are a type of white blood 
cells (lymphocytes) that fight against the infections. Studies have shown that HRS cells 
and L&H cells are derived from germinal center B-cells [16, 21]. However, they do not 
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possess B-cell ancestry [23, 24]. Malignant cells HRS and L&H constitute only 1% of the 
total cells in the tumor, making the diagnosis and identification of HL difficult [21]. But, 
advances in understanding of neoplasms have made it easier to accurately classify the 
subtypes of HL [25].  The only common feature between CHL and NLPHL is the low 
number of neoplastic cells [24]. 
     HL usually presents as a lymphadenopathy (swollen lymph nodes) which in turn may 
reveal mass lesion, can be detected by imaging procedures or symptoms (e.g., fever, 
fatigue). Each of the two major subtypes of HL has a unique group of symptoms and 
natural history [26]. For instance, a common clinical manifestation of the CHL is painless 
lymphadenopathy. NLPHL has a different natural history, e.g., indolent disease course 
which is different from that of CHL. The pattern in which the disease (both types) 
spreads throughout the body plays a critical role in effective diagnosis and treatment 
selection.  
    HL initiates at a single site (lymph node) and progresses to adjacent lymph nodes with 
the aid of lymphatic vessels. Late in the course of disease it disseminates to distant sites 
and organs. It spreads in a predictable manner, starting mostly in supradiaphragmatic 
(above the diaphragm) nodes (90%) and less often in infradiaphragmatic (below the 
diaphragm) nodes (10%) [26]. Extranodal (affecting other organs) spread of HL can 
happen in two ways: localized (direct invasion) and distant (hematogenous 
dissemination). Localized spread affects organs nearby cancerous lymph nodes (e.g., 
thyroid, skin). In distant spread of HL organs such as the spleen, liver, lung, bone marrow 
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or bone are involved. The symptoms of HL can be grouped as localized symptoms (e.g., 
cough, chest pain, bone pain, abdominal swelling), non-specific constitutional or organ 
related (e.g., fever, night sweats, weight loss, fatigue) and lab abnormalities. Patients with 
NLPHL rarely experience constitutional symptoms such as fever, weight loss, night 
sweats [19]. 
2.1.3 Prevalence and Incidence of Hodgkin Lymphoma     
       HL accounts for approximately 10% of all lymphomas and approximately 0.6 % of 
all cancers diagnosed in the world annually [22]. The global incidence of HL for both 
males and females varies with continents and geographical regions. According to 2008 
International Agency for Research on Cancer (IARC) statistics, incidence was highest in 
Southern Europe, followed by North America and lowest in East Asia[27]. The age 
standardized incidence rates in North America was 2.6 (per 100,000) for men and 2.2 
(per 100,000) for women [27]. 
    The US National Cancer Institute estimated that 8830 new HL cases occurred in 
United States and 1300 of the prevalent cases died from this disorder in 2011 [28]. In 
2010, the Canadian Cancer Society (CCS) estimated the incidence rate of HL to be 3 (per 
100,000) for both men and  women in Canada[1]. According to CCS, 960 new cases were 
diagnosed with HL and 116 of the cases died in 2010. Furthermore, CCS estimated the 
annual percentage of change in age standardized incidence rates to be 0.2% for men and 
0.4% for women based on data from 1997 to 2006. 
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2.1.4  Epidemiology and Risk factors of Hodgkin Lymphoma  
      Despite advances in medical sciences and technologies, the etiology of HL is not 
conclusive. The main known risk factors of HL are age, gender, socioeconomic status, 
race and ethnicity, family history and certain viruses such as human immunodeficiency 
virus (HIV) and Epstein - Barr virus (EBV) [29] that will be described in more detail 
below. 
HIV and EBV: There have been prospective cohort or registry match studies conducted 
on HIV patients around the world. A recent prospective cohort study showed that the risk 
of developing HL among the HIV infected patients is higher than that of general 
population [30]. The study reported that standardized rate ratio (SRR) was 14.7 (95% CI: 
11.6 to 18.2). Two systematic reviews have indicated that the risk of developing HL 
among the HIV infected population is approximately 8 to 15 times more than for the 
general population [31, 32]. 
       Some other studies have shown that there is a positive association between EBV 
status and HL [33]. However, the true  relationship between EBV and HL is still unclear 
[34] and the direct versus indirect effect of EBV on Hodgkin disease remains 
questionable. A prospective study from Brazil showed that prevalence of EBV is more 
apparent in HIV positive (100% versus 29%) and advanced stage (63% versus 9%) HL 
diagnosed patients. In general it has been shown that EBV is associated with between 
20% and 50% of HL cases in North America [35, 36]. 
9 
 
 
 
Age: One of the unique characteristics of the HL is that it has a bimodal age distribution 
[37-39]. The incidence is small among children, followed by a sharp increase in teenagers 
which reaches a peak at 25 years of age. Thereafter, incidence falls between the ages of 
25 and 70 and then increases again after the age of 70, peaking in the late 70s. This 
variation can be explained by different pathogenesis of the disease in the two separate 
populations [40].                                    
Gender: HL incidence is higher among males than among females [41]. Some 
researchers explained this phenomenon by the role of reproductive factors  and sex 
hormones [42]. According to 2010 CCS statistics, 540 males and 420 females were 
diagnosed with HL cancer [1]. Furthermore, according to US National Cancer Institute 
SEER (Surveillance Epidemiology and End Results) estimates, males on average were 
1.22 to 1.25 times more likely to develop a HL cancer than females [43].    
Socioeconomic Status (SES): HL incidence may vary with socioeconomic status. Age 
specific incidence rates from one study were highest in high socioeconomic group across 
the all ages [44]. Using SEER data Glaser et al. (1987) showed that HL incidence was 
positively associated with community level socioeconomic status [45]. 
Race/Ethnicity: Disease incidence varies with race and ethnicity (Table 2-1). A 
Canadian case control study showed that HL incidence is higher among people of Eastern 
and Western European descent [46]. Blacks tend be less susceptible than whites and this 
might be partially explained by genetic factors or socioeconomic status [47]. According 
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to 2004-2008 US National Cancer Institute statistics data, incidence rates were highest 
among whites (3.3 per 100,000 men and 2.8 per 100,000 women) and lowest among the 
Asian/Pacific Islander (1.5 per 100,000 men and 1.1 per 100,000 women)[43].  
Table 2-1: Incidence by Race 
  
Incidence (per 100,000) 
Race/Ethnicity Males Females 
All 3.1 2.6 
White 3.3 2.8 
Black 3.2 2.4 
Asian/Pacific Islander 1.5 1.1 
American Indian/Alaska 
Native 1.0 N/A 
Hispanic 2.7 2.2 
                                        Source: 2004-2008 SEER data [43] 
Family History: Genetic susceptibility is an important predictor of HL. The risk of 
developing disease increases threefold if a first degree relative (e.g., parent, sibling, 
offspring) has the disease [22]. Risk is especially higher in twins and siblings but lower in 
older parents.  
A familial risk study conducted using cancer registry data from Sweden and Denmark, 
has shown that the relative risks of HL in relatives of HL patients were 3.47 (95% CI: 
1.77- 6.80) in Sweden and 2.55 (95% CI: 1.55-6.05) in Denmark [48]. 
Smoking: Several studies indicated being a current or former smoker is positively 
associated with risk of HL [49, 50]. However, other studies showed no association or 
inverse association [51, 52]. 
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BMI: The effect of BMI is not conclusive. In a Swedish cohort study relative risk of HL 
was 3.3 (1.4-6.5) among the obese men (BMI > 30 kg/m2) and 0.9 (0.3-2.4) among obese 
women (BMI>28.6 kg/m2) [53]. However, a Scandinavian case control study showed that 
there was no association between obesity and risk of HL [54].  
Occupation: It has been shown that certain occupation exposures can also play a role in 
the development of HL [55, 56]. These studies showed that several environmental 
exposures such as uranium ionizing radiation and gasoline station occupation are 
associated with increased risk of HL. 
2.1.5 Diagnosis of Relapsed and Refractory Hodgkin Lymphoma 
    Initial evaluation of patient starts with physical examination for swollen lymph nodes, 
presence or absence of systemic symptoms (e.g., fever, night sweats, and weight loss) and 
any history of past malignancy. About one third of patients develop systemic symptoms 
and these symptoms are associated with poor prognosis [19, 57]. Definitive diagnosis of 
HL is established either by excisional (entire lymph node) or incisional (part of a lymph 
node) biopsy. In addition, blood tests are conducted to count the number of blood cells 
which may provide supportive evidence for cancer. Finally, imaging tests (e.g., CT, PET) 
shows swollen lymph nodes and allows determining the tumor burden. Once diagnosis of 
disease is established, clinical stage of HL is determined in order to determine 
appropriate treatment strategy.  
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     Clinical staging of HL is an important factor that measures the burden of disease and 
prognosis prediction. In 1971, the Ann Arbor Staging system was introduced [58] and 
later in 1989 the Cotswolds modification of the Ann Arbor staging system was  
introduced [59].  This is still used for staging of Hodgkin cancer (Table 2-2).  
Table 2-2 : Staging System 
Stage Definition 
I Involvement of a single lymph node region (I)  or single extralymphatic site (Ie) 
II 
Involvement of two or more lymph node regions on the same side of the 
diaphragm (II) or of one lymph node region and a contiguous extralymphatic site 
(IIe) 
III 
Involvement of lymph node regions on both sides of the diaphragm, which may 
include the spleen (IIIs) and/or limited contiguous extralymphatic organ or site 
(IIIe, IIIes) 
IV Widespread involvement of one or more extralymphatic organs 
The absence of systemic symptoms is represented by adding 'A' to the stage; the presence of 
systemic symptoms is represented by adding 'B' to the stage. Bulky disease is denoted by 'X'. 
The subscript ‘E’ is used if limited extranodal extension is documented. ‘S’ means disease has 
spread to the spleen.  
    Diagnosed patients are placed into one of four stages (I-II-III-IV) based upon number 
of lymph nodes involved, presence or absence of systemic symptoms (e.g., weight loss, 
night sweats and fever),  bulky disease and extranodal involvement. Patients with stage I 
and II are further classified as favorable and unfavorable prognosis based on presence or 
absence of specific clinical features.  
      According to the German Hodgkin Lymphoma Study Group (GHSG) unfavorable 
prognosis is defined as if one of these criteria is met: large mediastinal mass, extranodal 
disease, higher erythrocyte sedimentation rate and at least 3 sites involved. The European 
Organization for Research and Treatment of Cancer (EORTC) definition is similar and it 
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includes age of 50 years old instead of extranodal disease and at least 4 sites involved 
instead of 3. The adverse prognostic factors for advanced HL are age of 45 years or older, 
stage IV disease, male sex, white blood cells count (at least 15,000 per m3), lymphocyte 
count (less than 600 per m3), albumin level (less than 4 g per dl) and hemoglobin level 
(less than 10.5 g per dl) and patients with at least 5 of the factors had 5-year overall 
survival (OS) of 56% versus 89% for patients with none of these factors [60]. More than 
80% of patients of patients less than 60 years old diagnosed with HL for the first time are 
cured from HL [19]. At least 50% of recurrent HL cases happen during first 1 to 2 years 
and up to 90% of recurrent HL cases seen after 5 years of the completion of primary 
therapy [26].       
     The US National Comprehensive Cancer Network (NCCN) guidelines are frequently 
used for diagnostic workup [61]. According to NCCN v3.2011 guidelines, an integrated 
PET-CT or a PET with diagnostic CT is recommended as the standard of surveillance 
imaging. Chest x-ray or CT every 6-12 months (during first 2-5 years) and CT abdominal 
every 6-12 months  (during first 2-3 years)  are follow up recommendations after the 
primary treatment [62], although some studies showed that serial imaging has limited 
value in detecting the recurrence of HL [63, 64]. 
     Re-biopsy is suggested for all patients to establish recurrence of the HL. However 
clinical researchers recommend use of the repetitive biopsy only in certain conditions 
such as unclear primary diagnosis, late relapse or possible alternative diagnosis  since it is 
an invasive procedure with possible risk of complications [61]. 
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      The popularity of PET scans has risen in the post-treatment period to assess the 
response to a treatment. The International Harmonization Project in Lymphoma 
consensus guidelines recommend scanning 6-8 weeks after chemotherapy and 8-12 
weeks after radiation [65]. The positive predictive value of the FDG-PET is variable and 
hence, it is recommended for FDG-PET positive patients to undergo biopsy or serial 
imaging until disease progresses.  
2.1.6 Prognostic Factors in Relapsed and Refractory HL 
       Multivariate analyses have shown that poor performance (measured by the 
Karnofsky performance score) status at relapse, age > 50 years and primary treatment 
failure were significant prognostic factors [66]. The 5-year OS was 55% for patients with 
none of these risk factors versus 0% for patients with all of the risk factors. A study of 
422 patients conducted by German Hodgkin Lymphoma Study Group (GHSG)  showed 
that anemia, advanced clinical stage (III-IV) and time to treatment failure (< 12  months) 
at relapse were significant prognostic factors  [67]. Factors such as B-symptoms and age 
were shown to be predictors of the poor outcome by some studies if not by all [68]. 
Therefore, further prospective validation is necessary for these determinants. However, 
time to relapse, advanced stage and poor performance status are shown to be robust 
predictors and can be utilized in risk adapted treatment approach [61].  
2.2 Treatment Options 
     Survival rates of HL patients have improved after the introduction of combined 
modality therapy (CMT). About 80 to 90% of the patients can be treated with standard 
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treatment options and the remaining is disease refractory [4]. We described first, second 
and third line treatment options (Figure 2-1) in detail in the following sections. 
 
 
 
 
2.2.1 First Line Treatments 
      In recent years, risk adapted therapies have been extensively used as new first line 
treatment options and more accurate staging techniques have emerged for HL patients. 
For favorable early-stage (stages I-IIA) HL patients short term chemotherapy followed by 
involved-field radiotherapy (IFRT) is considered as standard front line treatment [69, 70]. 
Combination chemotherapy consists 2 to 4 cycles of ABVD (doxorubicin, bleomycin, 
vinblastine, and dacarbazine) followed by dose of 30 Gy radiotherapy [71]. Commonly 
adopted regimen for early stage (I and II) unfavorable HL patients is combination 
chemotherapy with 4 to 6 cycles of chemotherapy regimen followed by IFRT with the 
dose of 30 Gy [71, 72].  
       For advanced stage (III-IV) patients, MOPP (mechlorethamine, vincristine (oncovin), 
procarbazine and prednisone) was the first regimen employed. The ABVD regimen 
(doxorubicin, bleomycin, vinblastine, and dacarbazine) showed superior results in terms 
Figure 2-1: Treatment Pathway 
FIRST LINE                                      SECOND LINE                            THIRD LINE 
 Chemotherapy 
and/or Radiotherapy 
Salvage Chemotherapy 
HDC +Autologous SCT 
Allogeneic SCT 
Tandem SCT 
Palliative regimens 
16 
 
 
 
of efficacy and acceptable toxicity to MOPP and therefore became the standard regimen 
for advanced HL patients [73]. Currently, the most frequently employed treatment 
regimen in North America and Europe is eight cycles of ABVD plus consolidative 
radiotherapy for residual disease [71]. The alternative regimens are Stanford V 
(mechlorethamine, adriamycin (doxorubicin), vinblastine, vincristine, bleomycin, 
etoposide, prednisone, G-CSF) and BEACOPP (bleomycin, etoposide, adriamycin 
(doxorubicin), cyclophosphamide, oncovin (vincristine), procarbazine, prednisone, G-
CSF). 
2.2.2 Second Line Treatments 
      Although the majority of patients diagnosed with HL attain complete remission after 
the first line therapy, approximately 15% of early stage HL and up to 50% of advanced 
stage HL patients relapse following initial therapy [2, 3].  
2.2.2.1 Salvage Chemotherapy 
     Despite the number of regimens available there is no consensus on optimal salvage 
chemotherapy regimen. Most of these regimens are tested in non-randomized and single 
arm trials that resulted in overall response rates varying from 69% to 81%. Thus, it is 
difficult to conclude which regimen is preferable since there is no head to head 
comparison between regimens. Death rates related to toxicities varied from 0% to 5% 
among available salvage regimens. According to documented salvage chemotherapy 
regimens, there appears to be a tradeoff between the toxicity level and higher response 
rates, since an increase in dose of chemotherapy regimen results in more deaths. The 
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major observed toxicities in these salvage regimens were grade III-IV neutropenia, 
thrombocytopenia and vomiting. Dose escalation may result in gains in efficacy, but 
comes with the cost of toxic effects. The goal of the salvage treatment is an important 
criteria in selection of the treatment regimen. For instance, if the goal of salvage is to 
enable patient to proceed to ASCT then regimen must have acceptable level of 
hematological toxicity so that it does not impair ability for stem cell mobilization. Hence, 
efficacy must be balanced with toxicity. The key characteristics of salvage chemotherapy 
regimens are listed in Table 2-3. 
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Table 2-3: Salvage Chemotherapy Regimens 
Salvage 
Regimen # of Patients 
 
 
Age 
range CR (%) PR (%) 
 
 
 
Regimen 
 
 
TRM 
(%) 
 
 
Type of  
Study 
Year of 
Publication Reference 
Dexa-BEAM 144 16-60 27 78 dexamethasone and carmustine, 
etoposide, cytarabine, melphalan 5 RCT 2002 [74] 
DHAPq2wk 102  21-64 21 68 dexamethasone, cisplatin, cytarabine 0 Phase II 2002 [75] 
GDP 23 19-57 17 52 gemcitabine, dexamethasone, cisplatin 0 Phase II 2003 [76] 
GVD 91 19-83 19 51 gemcitabine vinorelbine pegylated liposomal doxorubicin 0 Phase I/II 2006 [77] 
ICE 65 12-59 26 58 ifosfamide,carboplatin and etoposide 0 Prospective Trial 2001 [78] 
IVE 51 16-53 61 NR ifosfamide, etoposide and epirubicin 0 Prospective Trial 2003 [79] 
MINI BEAM 55 15-60 51 33 BCNU (carmustine), etoposide, 
cytarabine and melphalan 2 Prospective Trial 2001 [80] 
MINE 157 15-65 NR NR mitoguazone, ifosfamide, vinorelbine 
etoposide 5 Prospective Trial 2002 [81] 
IV 47 NR 45 38 vinorelbine, ifosfamide NR NR 2001 [82] 
CR: Complete Remission, PR: Partial Remission, TRM: Treatment Related Mortality, NR: Not Reported 
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2.2.2.2 High Dose Chemotherapy and Autologous Stem Cell 
Transplantation  
      To our knowledge there have been two RCTs conducted to examine efficacy of the 
high dose chemotherapy regimen followed by stem cell transplantation in relapsed and 
refractory patient population [74, 83]. Therefore, carmustine (BCNU), etopside, 
cytarabine and melpahalan (BEAM) is considered as a standard high dose regimen in this 
setting [61] and BEAM regimen followed by ASCT is considered standard of care for 
patients following the relapse after the first line therapy. 
     The first clinical trial of high dose chemotherapy (e.g., BEAM) was conducted by 
British National Lymphoma Investigation (BNLI) by randomizing 40 patients to BEAM 
followed by stem cell transplantation and to Mini-Beam treatment arms. Patients were 
followed up for the median length of 34 months. Two patients died due to toxic effects of 
bone marrow transplantation. Event free survival (EFS) at 3 years was 53% and 10% for 
Beam plus ABMT and mini-Beam arms respectively. Both EFS and PFS were superior in 
Beam plus ABMT treatment group (p=0.025 and p=0.005). 
      In another trial, GHSG randomized 161 patients to two cycles of Dexa-BEAM 
(dexamethasone and carmustine, etoposide, cytarabine, and melphalan). Responded (or 
chemo-sensitive) patients received either two more cycles of Dexa-BEAM or high dose 
BEAM followed by ASCT. Bone marrow or progenitor cells were harvested after the 
second cycle of Dexa-BEAM and patients received either autologous bone marrow or 
peripheral blood proginetor cells transplantation following the high dose chemotherapy. 
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Median follow up of patients was 39 months. OS at 3 years was 65% for Dexa-Beam and 
71% for high dose BEAM followed by ASCT. Freedom from treatment failure (FFTF) at 
3 years was 34% for Dexa-BEAM and 55% for high dose Beam followed by ASCT. 
Difference in OS was not statistically different between treatments (p=0.331). One out of 
61 patients (2%) died due to toxic effects of HDCT plus ASCT.  
      In each of these trials refractory patients were excluded from study. The evidence of 
efficacy of high dose regimen and ASCT among refractory patients is very limited. Like 
salvage regimens, there is no one-to one comparison of high dose regimens in 
randomized control setting. The efficacy and toxicity of the high dose regimens are 
highly variable. Other reported high dose regimens are CBV (cyclophosphamide, BCNU, 
VP-16; OS: 45%, FFS: 25% at 4 years), CBVP (cyclophosphamide, BCNU, VP-16, 
cisplatin; DFS: 39% at 4 years), CCV (cyclophosphamide, CCNU, VP16; OS: 57%, EFS: 
52%, FFP: 68% at 3 years), TLI-total lymphoid irradiation with VP16/CY  (OS: 81%, 
EFS: 68%), VP-16 and melphalan (DFS:38.4% at 4 years) and high dose melphalan-
HDM (OS:57%, EFS:52% at 5 years) [78, 84-88]. 
2.2.2.3 Standard Dose Treatments 
     GHSG reported that salvage radiotherapy (SRT) could be a treatment strategy for 
subset of relapsed and refractory patients, in particular for those with limited stage late 
relapses, without B-symptoms and good performance status [89]. GHSG study found that 
FF2F and OS at 5 years were 28% and 51% respectively. Other studies have reported 
similar results. For instance, Wirth et al. (1997) reported that 5- year Failure Free 
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Survival (FFS) and OS of 51 patients receiving salvage radiotherapy were 26% and 57% 
respectively [90]. Leigh et al. (1993) showed that 28 patients who received salvage 
radiotherapy in previously un-irradiated areas after failure to combination chemotherapy 
had 5-year relapse free survival (RFS) of 40% and OS of 63% [91]. Brada et al. (1992) 
analyzed 44 patients who received salvage radiotherapy after relapsing from 
chemotherapy and reported that 5-year PFS rate was 38% [92]. In addition, these studies 
showed that B-symptoms, advanced stage and poor performance status are important 
predictors of salvage radiotherapy. Moreover, it can be employed as a treatment option if 
the relapsed area was not previously irradiated. 
      There is limited data showing effect of conventional dose combined modality therapy 
as a second line therapy for relapsed and refractory patients. Moreover, these studies 
were conducted retrospectively. For instance, Bonfante et al. (1997) showed that standard 
dose chemotherapy can be treatment option for patients in long term complete remission 
(greater than 12 months) [93]. In their series of 115 patients who were re-treated with 
MOPP-ABVD, it was reported that 8–year OS was 54% for those in remission greater 
than 12 months and 28% for those in remission shorter than 12 months. 
     Likewise, series from Croatia reported outcomes of 65 relapsed and refractory patients 
who received MOPP followed by radiation as a primary treatment and continued with 
MOPP and ABVD as a second-line treatment [94]. Out of 65 patients 51% had complete 
remission, with OS and FFS at 10 years being 21% and 16% respectively. Prognosis was 
good for patients remaining in remission for more than 12 months versus for patients 
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remaining in remission for less than 12 months. Thus, it is concluded that conventional 
dose salvage chemotherapy followed/or not followed by radiotherapy is a treatment 
option for patients with late relapse and favorable prognosis.  
2.2.3 Third Line Treatments 
     Patients who relapse from autologous stem cell transplantation (ASCT) have very 
limited treatment options and available therapies are ultimately non-curative. Disease 
recurs in 50% of patients who underwent ASCT [5]. Prognosis for these patients is 
usually poor with median survival less than a year [6, 7]. More recent study showed that 
median survival is 26 months after autologous stem cell failure [95]. 
2.2.3.1 Allogeneic Stem Cell Transplantation    
       A study explored survival outcomes of cohort of 114 patients who relapsed after 
autologous stem cell transplantation and underwent myeloablative allogeneic stem cell 
transplantation [8]. PFS and OS at 3 years were 33% and 25% respectively. Treatment 
related mortality (TRM) was 22% at the end of follow up. The study concluded that only 
a small proportion of patients can benefit from allogeneic transplant in particular, patients 
with Human Leukocyte Antigen (HLA) matched sibling donor and good performance 
status. 
      Studies have shown that reduced intensity allogeneic stem cell transplantation (RIC-
allo) had much better survival, safety and lower treatment related toxicity than 
myeloablative allogeneic transplantation [96, 97]. There are several prospective trials 
23 
 
 
 
conducted to explore the effect of the reduced intensity regimens fludarabine and 
melphalan. Peggs et al.(2005) documented that 49 patients, 90% of whom had autologous 
transplantation before and failed, received fludarabine (150 mg/m2) and melphalan (140 
mg/m2) before allogeneic SCT [98]. Treatment related mortality was 16% at 2 years. OS 
and EFS at 4 years was 56% and 39% respectively. Similarly, Alvarez et al. (2006) 
reported that reduced intensity regimen resulted in mortality rate of 25% at 1 year and 
relapse rate of 68%. Furthermore OS at 2 years was 48% in this study [99]. Finally, 
Armand et al. (2008) estimated that  PFS was 22% and OS was 48% at 2 years with 
treatment related mortality of  25% at 1 year [9]. 
2.2.3.2 Tandem Autologous Stem Cell Transplantation 
      Treatment options for the patients relapsing after autologous transplantation are 
severely limited. Widespread use of allogeneic transplantation is not accepted due to 
treatment related mortality, lack of donor availability and graft versus host disease. 
Studies exploring the effect of the second stem cell transplantation are of limited number 
and most are from single institution.  
      Recently, a Center for International Blood and Marrow Transplant Research 
(CIBMTR) study investigated the survival outcomes of patients who underwent second 
autologous stem cell transplantation [11]. A total of 49 patients (53% Hodgkin 
Lymphoma versus 47% Non-Hodgkin Lymphoma) patients reported to CIBMTR 
between 1986 and 2003 that underwent second autologous transplantation. Median 
follow up of patients were 72 months. OS and PFS at 5 years was 30% and treatment 
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related mortality (TRM) was 11% at day 100. PFS at 5 years for patients relapsing (<12 
months) and (>12 months) after first transplant was 0% and 32% respectively.  
2.2.3.3 Palliative Regimens 
     A minority of patients will be eligible for allogeneic transplantation after autologous 
graft relapse. These patients, along with those not eligible for stem cell transplantation 
cannot be cured by standard treatment options. Agents used in non-curative setting 
include gemcitabine, vinorelbine and vinblastine. 
     Little et al. (1998) explored the efficacy of vinblastine by retrospective chart reviews 
of patients  who relapsed after transplantation [100]. It has been shown that EFS and OS 
were 8.3 months and 38.8 months respectively, with median follow up of 20.4 months. 
The toxicity of the vinblastine was well tolerated and therefore, vinblastine is considered 
as an effective palliation regimen. Zinzani et al. (2000) investigated gemcitabine on 14 
patients in phase II clinical trial [101]. Treatment resulted in overall response rate of 
43%. There was no severe toxicity reported other than myelosuppression. Despite the 
lower sample size and short follow up period gemcitabine is commonly accepted and 
widely used palliative agent. A study by Devizzi et al. (1994) evaluated vinorelbine on 24 
patients and showed that 11 out 22 patients had objective response [10]. The median 
duration of response was 6 months. The toxicity was mild and largely reversible. 
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2.2.3.4 Antibody Therapies and Investigational Agents 
     Rituximab has been shown to be somewhat effective in treatment of classical HL with 
response of 22% and median duration of 7.8 months [12]. However, it has been shown to 
be highly effective in the treatment of nodular lymphocyte predominant HL [102]. The 
response rate was 94% and median PFS was 33 months. Bortezomib was shown to be 
unsuccessful for the treatment of HL [13, 103]. An anti CD30 monoclonal antibody 
MDX-60 and SGN-30 had very low antitumor effect [104, 105]. 
2.3 Brentuximab Vedotin (SGN-35) 
       A monoclonal antibody targets a specific antigen that is present on the surface of 
cancer cells. Several monoclonal antibodies such as anti CD20 specific rituximab for 
non-Hodgkin Lymphoma demonstrated clinical success [106]. CD30 is an antigen 
expressed on the surface of malignant cells of HRS, cells of anaplastic large cell 
lymphoma (ALCL) and other lymphoid malignancies [107]. First generation of anti 
CD30 monoclonal antibodies (e.g., SGN-30, MDX-30) was unconjugated and resulted in 
minimal antitumor activity. This fact enhanced the efforts that yielded the development 
of conjugated monoclonal antibodies (mAbs). Antibody Drug Conjugate (ADC) 
treatment approach overcomes some of the limitations caused by systemic chemotherapy. 
In particular, toxicity is reduced due to targeted attack of conjugated chemo agents. There 
are 3 key components of ADCs: monoclonal antibody, cytotoxic drug and linker [108]. 
Recent developments in this field increased number of ADC drugs under the 
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development. Brentuximab Vedotin for HL, Trastuzumab-DM1 for breast cancer and 
Inotuzumab ozogamicin for non-Hodgkin lymphoma are some of the examples.  
       Brentuximab Vedotin (a.k.a SGN-35) is an ADC composed of anti CD30 anitbody 
cAC10 conjugated with anti-tubulin agent called monomethyl auristatin E (MMAE) by 
cleavable dipeptide linker [109, 110]. After antibody cAC10 binds with CD30, ADC is 
rapidly transported into lysosomes and cleavable linker is cleaved, releasing MMAE into 
the cell. The free potent agent MMAE, after binding with tubulin disrupts the 
microtubulin network within cell that results in apoptotic death of CD30 positive tumor 
cells [110]. This drug has been developed by Seattle Genetics Inc. (Bothell, WA) and 
Millennium: Takedo Oncology Company. 
       Clinical studies of brentuximab yielded encouraging results from phase I and the 
pivotal phase II trials [14, 111]. The target population in phase I trial (n=45) were those 
who relapsed and were refractory to the first line chemotherapy, high dose chemotherapy 
stem cell transplantation or salvage chemotherapy regimen. The median age of patients 
included in the trial was 36 years (20 to 87). All of the patients underwent median of 3 
previous chemotherapy regimens and 73% had undergone autologous stem cell 
transplantation. Patients receiving allogeneic stem cell transplantation were not included 
in phase I study. Brentuximab was administered intravenously every 3 weeks. The 
treatment was associated with mild to moderate toxicity levels, e.g., fatigue, nausea, 
diarrhea, neutropenia and peripheral neuropathy. According to dose escalation study 
maximum acceptable dose of brentuximab vedotin was 1.8 mg/kg. The median duration 
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of the objective response was at least 9.7 months and median PFS was 5.9 months. 
Overall, 86% (36 out 42) patients in the trial had a tumor regression. 
     Results of the pivotal phase II trial were consistent and verified the initial findings 
from the phase I trial [14]. A total of 102 patients with the median age of 31 years 
received a brentuximab vedotin at the dose of 1.8 mg/kg every 3 weeks for up to 16 
cycles. All of the patients received median of 4 (range: 1 to 13) prior chemotherapy 
regimens and autologous stem cell transplantation. More than 70% of the patients were 
primary refractory and in addition 39% of the patients did not respond to the most recent 
salvage therapy, excluding ASCT. Reported treatment related adverse events were 
peripheral sensory neuropathy, fatigue, nausea, neutropenia, diarrhea and pyrexia. 
Observed grade IV treatment-related events were neutropenia, and thrombocytopenia, 
abdominal pain, and pulmonary embolism. A total of 20% of the patients discontinued 
the treatment due to treatment related adverse event. Peripheral sensory neuropathy was 
the main reason for stopping treatment. 
     In August 2011, US FDA granted fast track approval to brentuximab veotin (Adcetris) 
at the dose level of 1.8 mg/kg for two indications: for patients with HL that failed after 
autologous stem cell transplant (ASCT) and for patients (not eligible for ASCT) who 
failed at least two prior multi agent chemotherapy regimens. In other words the new drug 
will be prescribed to patients only after the second relapse (Figure 2-1). Brentuximab 
Vedotin is also being clinically tested in a randomized setting and in combination with 
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multi agent chemotherapy regimen ABVD for potential use in the frontline treatment 
portfolio.         
2.4 Economic Evaluation and Cost-Effectiveness Analysis  
      The goal of the economic evaluation is to prioritize resource allocation by assessing 
the value for money of alternative healthcare programs [112]. There are several different 
types of economic evaluation. Cost effectiveness analysis (CEA) is among the most 
common type of economic analysis [113]. CEA compares alternatives with the same 
health outcome measure (e.g., life years gained, lives saved). The outcome measure in 
CEA is presented in the form of a ratio called the incremental cost-effectiveness ratio 
(ICER). The ICER provides incremental cost per additional unit of health benefit (e.g., 
life years saved) by adopting a new health technology under the consideration. 
OldNew
OldNew
EffectEffect
CostCostICER
−
−
=  
The perspective taken in economic analysis is important and different viewpoints may 
yield different results. Common viewpoints include that of the patient, hospital/clinic, 
healthcare system or society. Most guidelines advocate a societal perspective[114], but in 
practice many CEA analyses are done from health system perspective [115, 116].     
2.4.1 Interpretation of the ICER and Value Judgment 
      If the denominator of the ICER is negative and numerator is positive then the new 
technology is more costly and less effective than comparator and hence, it should not be 
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adopted. If the denominator of the ICER is positive and numerator is negative, then the 
new technology is less costly and more effective than comparator and the proposed 
medical technologies should be adopted. One faces a challenging decision when new 
strategy results in both higher costs and higher effectiveness (or less effective and less 
costly). The decision then becomes is to whether additional benefit in health outcome is 
worth paying (e.g., value judgment).  
      There are a number of ways to decide whether the ICER for the given treatment 
option is cost effective and hence, treatment should be adopted. One approach is the 
league table approach which is the list of cost per QALY values in the increasing order 
for all interventions and treatments with the lowest cost per QALY are selected until 
budget is exhausted [117]. It helps the decision makers to compare the ICER of the new 
technology to previously approved interventions to make a judgment whether it shows 
good value for money.  
      However, this approach is rarely used in practice since there is a variation in 
methodology of the source studies in the league table [112] and some decision making 
guidelines is used to assist decision. A willingness to pay (WTP) threshold is used in 
some countries. In the UK, medical technologies that cost less than £30,000/QALY are 
considered to be cost-effective [118]. In Canada, interventions with ICERs smaller than 
$20,000/QALY are often classified as having “strong evidence for adoption and 
appropriate utilization” and those with ICER greater than $100,000/QALY are classified 
as  having “weak evidence for adoption and appropriate utilization”[119]. 
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2.4.2 Quality Adjusted Life Years 
    The quality adjusted life year (QALY) is defined as measure of a person’s length of 
life weighted by a valuation of their health-related quality of life [113, 120]. It takes into 
account quality and quantity of life generated by new treatment and is the arithmetic 
product of life expectancy and measure of quality of life. QALY places different utility 
weights (continuous measure varying between 0 and 1) to different health states. A year 
of perfect health is represented by 1. Any value less than 1 represents non-perfect health 
status and death is considered to be equivalent to 0.  
2.4.3 Decision Analytic Models 
      Decision analytic modeling has been extensively used for clinical and 
epidemiological applications. It is widely utilized to compare competing alternatives with 
respect to costs, life years, QALYs and to estimate ICER. The most commonly used 
models include decision trees and Markov models, as well as combination of these. 
2.4.4 Markov Models       
     In most cases, data are obtained from randomized clinical trials. However, one of the 
limitations of the clinical trial is relatively short follow up period. Use of Markov model 
is necessary to project long term impact of the new therapy and to avoid difficulties of 
recursive decision tree model. Markov model was introduced in 1983 to the medical 
decision makers and has been extensively used in therapeutic decision making since its 
introduction [121, 122]. Markov models simplified the modeling of stochastic 
(probabilistic) events that may occur repeatedly and over the long time horizon (time 
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frame). Clinical events of interest with ongoing risk are modeled as a Markov process. 
The underlying assumption of the Markov process is that it is sufficient to know the 
present health state of the patient in order to project entire path of the future health states. 
In other words prognosis of all patients in a state X is same regardless of their disease 
history. It is also assumed that patient is in one of the finite number of health states at a 
given point in time. Markov process evolves as patient transitions from one state to 
another. The finite time horizon is divided into equal discrete time intervals known as 
cycles which can be of any (day, week, month, and year) length. The probability of 
transitioning from one state to another in a given cycle is known as the transition 
probability, which is a time variant in real life. There is a cost and utility (expressed in 
quality of life weights) reward for being in each state in a given cycle. Total cost (or 
utility) per cycle is calculated by summing the multiplication of probability of being in a 
given state with the cost (or utility) of being in that state across all states. The ICER is 
estimated by dividing incremental total cost by incremental total effectiveness at the end 
of time horizon.                           
2.5 Economic Evaluation of HL Technologies 
     The number of studies that conducted economic analysis of HL treatments and 
technologies is very limited. Moreover, most of these studies are conducted in a 
European setting. 
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2.5.1 Treatments 
       Norum et al. (1995) conducted a cost-utility analysis using a data of 55 HL patients 
from a Norwegian hospital setting. Total treatment costs included cost of medication, 
treatment, hospital stay, hotel stay, radiotherapy and etc. EuroQol questionnaires and 
Visual Analogue Scale (VAS) instruments were used to measure quality of life. 
Estimated total cost varied between £7905 and £29,837 depending on disease stage. Total 
healthcare costs were higher in advanced staged disease (P=0.0006) because of increased 
number of relapses. Mean treatment cost for relapsed and non-relapsed patients were 
£27929 and £8210 respectively. Quality of life scores did not differ much with disease 
stage. Overall cost per QALY ranged from £795 to £1803 depending on assumptions 
about indirect benefit and discount rate utilized. 
      Another study was conducted in a UK setting explored the cost effectiveness of high 
dose chemotherapy in relapsed and refractory Hodgkin and non-Hodgkin Lymphoma 
patients [123]. The baseline ICER was £12,800 and £17,600 per life year gained. 
Sensitivity analyses showed that HDC is cost effective at varying marginal cost and 
benefit levels. In particular, for the marginal benefit of 0.8 life years gained and for the 
marginal costs of between £10,000 and £16,000, high dose chemotherapy is cost effective 
and is below the accepted UK cost effectiveness threshold. 
      The study by van Agthoven et al. (2001) conducted cost effectiveness analysis by 
comparing costs and quality of life of PBSCT and ABMT for relapsed and refractory 
Hodgkin and non-Hodgkin Lymphoma [124] in a Dutch setting. A cohort of patients (91 
33 
 
 
 
transplanted) data registered in phase 3 randomized control trial was used to estimate 
costs and quality of life (QoL). Costs were estimated from institutional perspective and 
health related quality of life was estimated by SF-36, EuroQol and Rotterdam Symptom 
Checklist instruments in pre and post transplantation period. This study found that 
PBSCT results in both favorable costs and quality of life scores. Total costs per patients 
for PBSCT and ABMT treatment arms for the entire treatment were €33742 and €39610 
respectively.  
       Verenga et al. (2001) conducted an economic analysis comparing the PBSCT and 
ABMT treatment using the Hovon 22 study from Netherlands [125]. Data from cohort of 
204 patients with relapsed and progressive lymphoma (Hodgkin and Non-Hodgkin) that 
were in randomized phase 3 trial was used to conduct an economic analysis. Direct 
(personnel, materials, disposables, equipment, laundry and regular nutrition) and 
overhead costs were estimated from financial databases of two hospitals. Similar to van 
Agthoven et al’s findings, PBSCT had resulted in favorable costs and quality of life 
scores. Average total cost per patient was estimated as $13 954 (range: $4913 to $29 532) 
for PSCT and $17 668 (range: $10 170 to 44 082) for ABMT. The SF-36 and EuroQol 
scores did not significantly differ for the treatments, whereas on the RSCL scores PSCT 
patient quality of life was superior to that of ABMT. 
     A group of researchers studied the cost effectiveness of different treatment options for 
early stage HL patients [126]. Decision-analytic model was used to estimate lifetime 
costs and benefits. For pathologically confirmed stage I and II patients,  ICER of 
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laparotomy staging and tailored treatment compared with mantle and para-aortic-splenic 
(MPA) radiation therapy was $24,100/QALY and that of combined modality therapy 
(CMT) compared with laparotomy was $61,700/QALY. 
2.5.2 Imaging and Diagnostics 
       Dryver et al. (2003) explored the breakdown of follow up costs and the role of 
routine follow up imaging among HL patients  and reported that cost per true indication 
of relapse was $6000 and moreover, routine follow up tests were accountable for 84% of 
the total follow up costs [64]. 
       Guadagnolo et al. (2006) conducted a cost effectiveness analysis of the CT 
computerized tomography (CT) in the routine follow up of patients in the post primary 
treatment period [127]. They compared 3 strategies such as annual CT for 10 years, 
annual CT for 5 years and follow up with non-CT modalities. The study showed that for 
early stage patients routine follow up with CT was associated with increased costs and 
reduced QALYs and for advanced stage patients ICER was well above the accepted 
threshold.  Moreover, results were robust to the most of the variables. Overall, annual CT 
scan resulted in minimal survival benefit and CT was not recommended for routine use in 
diagnostic follow up.  
2.6 Summary 
    The number of treatment options for HL patients in the post ASCT failure period is 
limited. ASCT therapy cannot cure approximately half of the patients. The prognosis for 
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these patients is poor. Newly developed antibody drug conjugate brentuximab vedotin 
was approved for the use in US based upon phase II clinical trial. Initial findings showed 
that brentuximab can potentially be superior to existing treatment options. Economic 
evaluation of the drug has not yet been established.  
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Chapter 3  
3 Research Questions & Hypothesis 
3.1 Primary research question 
       To assess the potential cost effectiveness of brentuximab vedotin versus the standard 
of care in HL population failing ASCT, from a healthcare payer perspective in a Canada. 
3.2 Secondary research questions 
1.   To develop an “early look” model that will let us to project life time costs and 
benefits for patients who relapsed for the second time. 
2.   To identify the conditions under which this treatment will or will not be cost 
effective, as Canadian pricing is not yet available. 
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Chapter 4  
4   Methods  
4.1 Description of Model 
     We developed a Markov decision analytic model to project lifetime clinical and 
economic consequences of HL patients who received third line treatment. The model 
starts with a clinical decision to treat with brentuximab versus standard of care and it 
consists of two distinct Markov models, namely model M1 for brentuximab vedotin and 
model M2 for standard of care treatment options (Figure 4-1).  
     The decision analytic model was developed using software TreeAge Pro Suite 2009 
(TreeAge Software, Inc. Williamstown, MA). We ran the model for lifetime horizon. The 
model M1 simulates lifetime costs and benefits of patients receiving brentuximab 
treatment and includes four health states: (1) Patient shows improvement or remains 
stable, (2) patient develops treatment related serious adverse event which prevents 
him/her to continue treatment, (3) patient’s disease progresses (4) patient dies from HL 
cancer or from other causes (Figure 4-2). We assumed that peripheral sensory neuropathy 
is the only adverse reaction that stops patient from continuing treatment. The model M2 
simulates the lifetime economic and clinical outcomes of patients on standard of care 
option and includes three distinct health states: (1) Patient is free from treatment failure 
(FFTF), (2) patient’s disease progresses, (3) patient dies from HL cancer or other reasons 
(Figure 4-3). 
38 
 
 
 
 
Figure 4-1: Decision Tree 
 
Figure 4-2: Markov model M1 (brentuximab) 
39 
 
 
 
 
Figure 4-3: Markov model M2 (standard of care) 
4.2 Data Sources 
i) Description of  Source:   
The models were populated using brentuximab phase II clinical trial and administrative 
data from cd-link which is cancer data linkage (‘cd-link’) program that includes datasets 
relevant to cancers such as cancer registry and administrative databases of Ontario. 
The study was approved by the Research Ethics Board (REB) at the University of 
Western Ontario. A data request was submitted to cd-link in August 2011. We requested 
data for all patients diagnosed with HL (ICD-9 diagnosis code: 201) between January 1, 
2000 and December 31, 2006 along with follow up data until 31 March 2011. HL patients 
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are selected from Ontario cancer registry and linked to CIHI Discharge Abstract Database 
(CIHI-DAD), Ontario Health Insurance Plan (OHIP) and Ontario Drug Benefit (ODB) 
databases to estimate healthcare utilization, cost and transition probabilities (Figure 4-4). 
The CIHI-DAD database includes the hospitalization abstracts, OHIP keeps track of 
physician claims and ODB records the drug benefit claims. The cd-link data of patients 
are de-identified and made anonymous before being released to researchers. The National 
Ambulatory Care Reporting System (NACRS), Continuing Care Reporting System 
(CCRS), CytoBase (cervical screening), Home Care Database (HCD)/Ontario Home Care 
Administrative System (OHCAS), National Rehabilitation Reporting System (NRS), 
Ontario Breast Screening Program (OBSP) and Registered Persons Data Base (RPDB) 
are other available datasets through cd-link program for the researchers. We did not use 
these datasets in this study. 
 
 
 
 
 
 
 
Figure 4-4: Data Linkage Project 
Ontario Cancer 
Registry (OCR) 
 
CIHI Discharge Abstract Databases 
(DAD) and 
Same Day Surgery (SDS) 
 
 
Ontario Health 
Insurance Plan  
(OHIP) 
 
 
 
Ontario Drug 
Benefit (ODB) 
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ii) Cohort of Interest 
      According to US Food and Drug Administration (FDA)  brentuximab is approved for 
two indications:  i) for the treatment of HL after failure of ASCT  ii) for the treatment  
HL  after failure of two multi agent chemotherapy regimens in patients who are not 
ASCT candidates  [128]. The phase II trial of brentuximab included patients with 
autologous SCT failure history and hence we limited our cohort to patients who had 
ASCT failure. 
      Each permanent resident of Ontario is covered by the Ontario Health Insurance Plan 
(OHIP). To identify the cohort of interest we used the OHIP database of physician claim 
records. This database tracks the medical claims submitted by physicians for the 
reimbursement of the services provided to the patients. Each medical service has a 
specific fee for service code that indicates the labor cost of the medical service. 
Physicians must specify the service and relevant fee code for the service in claim form.  
The fee codes for chemotherapy, radiotherapy, stem cell transplantation and palliative 
treatments are summarized in Table 4-1. 
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Table 4-1: OHIP Fee Codes 
Code Explanation 
Chemotherapy  
 
G339 Single Agent High Dose 
G345 Complex single agent or multi agent therapy 
G359 Special singe agent or multi agent therapy with major toxicity 
G381 Standard chemotherapy (single injection)  agents with minor 
toxicity 
G281 Each additional standard chemotherapy agent other than initial 
agent 
G390 Supervision of chemotherapy agent for induction phase of acute 
leukemia or myeloablative therapy prior to bone marrow 
transplantation 
G075 Test dose once per patient per drug 
G382 Supervision of chemotherapy by telephone, monthly 
G388 Management of special oral chemotherapy, for malignant 
disease 
Radiotherapy 
 
X305 Intracavitary 1.st application 
X306 Intracavitary repeat application 
X322 Treatment Planning, dosage calculation and preparation of 
device 
X310 Level 1 :Simple  Treatment Planning  
X311 Level 2: Intermediate Treatment Planning 
X312 Level 3: Complex Treatment Planning 
X313 Level 4: Full 3D Treatment Preparation 
Stem Cell Transplantation 
Z426 Bone marrow transplantation, infusion into recipient 
Palliative Care 
 
A945 Special palliative care consultation (family and general practice) 
C945 Special palliative care consultation  (non-emergency hospital in-
patient) 
C882 Palliative care per visit, subsequent visit 
C982 Palliative care per visit, subsequent visit 
K023 Palliative care support per unit 
W872 Palliative care  (nursing home  or home for aged) 
W972 Palliative care per visit (nursing home or home for aged) 
subsequent visit 
W982 Palliative care per visit (chronic care or convalescent hospital) 
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W882 Palliative care per visit (chronic care or convalescent hospital) 
subsequent visit 
 
According to the OCR, 2475 patients were diagnosed with HL between January 1, 2000 
and December 31, 2006 (Figure 4-5). By linking the data of these patients with the OHIP 
database, we determined 176 medical claims with fee code Z426 that was associated with 
stem cell transplantation. The autologous SCT is always a preferred treatment option over 
allogeneic SCT due to lower treatment toxicity and is approved for second line treatment 
of HL in Ontario. Given that if one is eligible for SCT he will first undergo autologous 
SCT after the first relapse. Using service dates of stem cell transplantation procedures, 
we concluded that 163 patients received autologous SCT as a second line treatment. 
Amongst these patients, ones receiving the chemotherapy (with fee codes G075, G281, 
G339, G345, G359, G381, G382, G388 and G390) or second autologous or allogeneic 
transplant (with fee code Z426) or radiotherapy (with fee codes X310, X311, X312, 
X313, X305, X306, X322) in post autologous SCT period were considered as relapsed 
following the high dose chemotherapy and autologous stem cell transplantation (n=77). 
The baseline characteristics of the cohort of interest are summarized in Table 4-2. 
 
 
 
Jan 1, 2000 
              
  Follow up: 2 years 
Diagnosis data: 
ICD9-201; n=2475 
Dec 31, 2006 
              
Second line: ASCT; 
n=163 
Third line: CT, RT, SCT 
and Palliative; n=77 
Figure 4-5: Schematic representation of steps to capture the cohort 
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Table 4-2: Demographics and Clinical Characteristics of 77 Patients 
Variables 
  Value (%)  
Age-(years) 
 
 < 20 17 (22.08) 
 20-24 6 (7.79) 
 25-29 14 (18.18) 
 30-34 7 (9.09) 
 35-39 10 (12.99) 
 40-49 13 (16.88) 
 50-59 7 (9.09) 
 60-69 3 (3.90) 
Sex 
 
 
 Male 33 (42.86) 
 Female 44 (57.14) 
Time since initial diagnosis (years) 
 Median 1.61 
 Mean 2.06 
 Range 0.59-7.67 
Previous Therapy 
 Chemotherapy 76 (99) 
 Radiotherapy 15(20) 
 Transplantation 77 (100) 
Initial Diagnosis Year 
 2000 12 (15.58) 
 2001 10 (12.99) 
 2002 15 (19.48) 
 2003 8 (10.39) 
 2004 13 (16.88) 
 2005 10 (12.99) 
 2006 9 (11.69) 
Status on 31 March 2011 
 Alive 51 (66.2) 
 Dead 26 (33.7) 
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4.3 Survival Analyses & Transition Probabilities  
4.3.1 Cd-link Data    
We followed all patients for 2 years and conducted survival analysis. We obtained PFS 
(Figure 4-1), OS (Figure 4-7), Progression to Death (Figure 4-8) and FFTF to Death 
(Figure 4-9) survival curves using the physician claims database. Using physician billing 
codes we defined the progression endpoint if patient satisfied one or more of the 
following criteria:  
i)     If one received chemotherapy after 5 months following the start of third line 
treatment or difference in service dates of any two consecutive chemotherapy 
claims is at least 60 days. 
ii)     If one received radiotherapy (X305, X306, X322, X310, X311, X312, and 
X313) after the third line treatment. 
iii)    If one underwent transplantation (Z426) following the third line treatment. 
iv)     If one received palliative treatment (A945, C882, C945, C982, K023, W982, 
W882, W872, and W972) in the post third line therapy period. 
The above definition of progression is a proxy, since it assumes progression only when 
there is a treatment change. According to these criteria 40 (out of 77) patients developed 
progression at the end of follow up period and median PFS was 13 months. According to 
OHIP database 28 (out of 77) patients did not have any treatment records since start of 
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third line treatment. OS, Progression to Death and FFTF to Death survival at 2 years were 
80%, 76% and 83% respectively. 
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Figure 4-6: PFS of 77 patients from cd-link cohort 
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Figure 4-7: OS of 77 patients from cd-link cohort 
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Figure 4-8: Progression to Death of 77 patients from cd-link cohort 
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Figure 4-9: FFTF to Death based of 77 patients from cd-link cohort 
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4.3.2 Clinical Trial 
     In phase II clinical trial, the investigators conducted a subgroup analysis in which a 
subset of patients (n=57) underwent systemic therapy first and then received 
brentuximab. The response was assessed by CT and PET scans at a specified time 
intervals. The PFS was measured before and after the brentuximab treatment. The median 
PFS was 4.1 months for the systemic therapy and 7.8 months for brentuximab that 
yielded hazard ratio of 0.41. The PFS curves for both clinical cases are reported [14]. For 
the illustrative purposes all PFS curves are depicted in Figure 4-10. 
 
Figure 4-10: Illustrative PFS Curves from Phase II trial and cd-link data 
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4.3.3 Transition Probabilities for Markov Models 
      We fitted parametric Weibull distribution to the patient level data to predict the 
survival beyond the 24 months follow-up period for patients who developed progression 
and who were cancer free. To be consistent, we also estimated the survival distribution of 
patients on standard of care treatment arm (phase II clinical trial) by fitted Weibull 
distribution. The scale (λ) and shape (k) parameters and parametric survival curve are 
summarized in Figure 4-11, Figure 4-12 and Figure 4-13. 
 
 Figure 4-11: Comparison of Kaplan-Meir and parametric Weibull survival curve 
(patients developing progression) 
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Figure 4-12: Comparison of Kaplan-Meir and parametric Weibull survival curve (cancer 
free patients) 
 
Figure 4-13: Comparison of Kaplan-Meir and parametric Weibull survival curve 
(patients on standard of care treatment in phase II trial) 
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 In the base case scenario, we derived transition probabilities from “FFTF” to 
“Progression” state in model M2  from parametric Weibull survival curve of patients on 
standard of care treatment arm in phase II trial (Figure 4-13). We adjusted these transition 
probabilities for hazard ratio (hr=0.41) reported in clinical trial to estimate transitions 
from “Improve or Stable” to “Progression” state in model M1. The transition 
probabilities from “Progression” to “Death” were derived from fitted Weibull survival 
curve of patients who had progression (Figure 4-11). Similarly, we estimated the 
transition probabilities from “FFTF” to “Death” in model M2 from fitted Weibull 
survival curve of cancer-free patients. Since we run the model for lifetime horizon, the 
transition probabilities beyond the 24 months period were estimated from the predicted 
survival estimates. We assumed that patients who develop serious adverse reaction stop 
brentuximab treatment and switch to standard of care treatment and hence follow the 
same transition probability matrix as for model M2. According to phase II trial of 
brentuximab none of the patients died from drug related causes. Therefore, we used 
Ontario gender specific life tables to derive the transition probabilities from “Improve or 
Stable” to “Death” state in model M1 by accounting for gender distribution in the trial.  
4.4 Costs 
Standard of Care: Using Canadian Classification of Interventions (CCI) and OHIP fee 
codes we sub-classified the hospitalization and physician costs as relevant and other 
costs. Relevant costs are the direct costs associated with cancer treatment such as 
chemotherapy, radiotherapy and transplantation and other costs include costs related to 
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follow up tests, comorbidities, treatment of toxicities and etc. All costs are adjusted for 
inflation using health and personal care consumer price index (CPI) reported by Statistics 
Canada and expressed in 2012 CAD. Monthly average costs per subject for freedom from 
treatment failure and progression states are summarized in Table 4-3 and Table 4-4. To 
avoid the impact of monthly variations in costs on the ICER we used smoothing 
technique, averaging the costs in the first 5 months and in the following months (Table 
4-5).     
Hospitalization Cost: Resource Intensity Weight (RIW) was used to estimate the cost of 
hospital services. The costs were estimated using RIW from CIHI-DAD database and 
cost per weighted case (cpwc). After removing four hospital abstracts with missing riw 
values, a total of 213 hospital abstracts were associated with 58 patients in the cohort. We 
obtained cost per weighted case (cpwc) data for the fiscal years 2005-2010 from Hospital 
Financial Performance Indicators annual report released by CIHI. 
Physicians Cost: Physician labor cost was estimated by medical claims from OHIP 
database. A total of 25125 physician claims corresponding to all patients were used to 
estimate the cost. 
Drug Cost: In Ontario, people with age above 65, long term care residents, those 
receiving home care and people with limited income are covered by Ontario Drug Benefit 
(ODB) plan. The patients on standard of care had 3795 drug benefit claims that 
correspond to 39 patients in the cohort. We assumed that patients who are under 65 years 
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old and not covered by ODB will experience the average drug costs of patients who are 
under 65 and covered by ODB. 
Brentuximab: According to the US FDA brentuximab prescribing information patients 
receive treatment for maximum of 16 cycles, until patient develops serious adverse 
reaction or progression. The manufacturer revealed the cost of the brentuximab to be 
$13,500 US per dose or $4500 US per vial [129]. In the base case scenario we assumed 
that cost of brentuximab in Canada will be the same as in the US. Knowing that patients 
in the trial received 10 doses on average, we estimated average monthly cost of the drug 
to be US $ 18,000. Cost of the administration is estimated from internal costing by 
London Regional Cancer Program (LRCP) pharmacy. Infusion time cost for a 30 minute 
is $160 CAD and pharmacy preparation time cost is $35 CAD at LRCP. We assumed that 
serious adverse reaction, i.e., peripheral sensory neuropathy results in one time 
consultation visit, but not in hospitalization and these patients stop brentuximab, switch 
to standard of care as per phase II trial outcomes. 
 
 
 
 
54 
 
 
 
    Table 4-3: Average Monthly Cost ($, CAD) per Patient in FFTF State (77 patients) 
  
Hospitalization 
Cost Physician Cost Drug Cost 
Months Relevant Other Relevant Other       Total 
1 1511.37 257.028 659.241 390.239 188.258 
2 43.748 968.983 47.0449 944.373 115.311 
3 522.46 616.601 61.7026 437.435 96.213 
4 502.357 654.01 19.6078 289.18 92.3373 
5 0 3593.15 10.6438 1264.66 87.413 
6 0 239.459 295.71 364.495 105.401 
7 199.042 254.62 32.7648 241.362 104.029 
8 0 339.295 1.90753 223.921 135.367 
9 0 0 2.35742 113.578 98.6971 
10 0 0 0 171.731 100.89 
11 0 0 0 143.102 101.085 
12 0 346.375 1.52882 1327.38 101.158 
13 0 0 0 108.224 105.543 
14 0 1078.28 0 107.07 104.787 
15 0 0 0 191.569 104.873 
16 0 40.6103 0 186.064 106.825 
17 0 326.693 0 229.392 106.825 
18 0 0 0 95.9656 106.825 
19 0 0 0.39686 60.3808 106.825 
20 0 0 0 118.852 110.074 
21 0 0 0 110.357 141.015 
22 0 0 0 120.676 161.988 
23 0 0 1.71992 84.418 113.501 
24 0 0 0 54.9987 124.298 
Total 2778.977 8715.104 1134.6255 7379.423 2719.538 
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Table 4-4: Average Monthly Cost ($, CAD) per Patient in Progression State (40 patients) 
  Hospitalization Cost Physician Cost Drug Cost 
Months Relevant Other Relevant Other       Total 
1 0 0 4.12782 35.0767 16.0098 
2 0 0 23.4119 68.442 96.9649 
3 0 414.078 102.857 176.476 191.933 
4 0 209.623 25.803 336.121 159.272 
5 0 153.718 23.6171 186.617 116.953 
6 0 710.931 9.81618 439.341 202.486 
7 0 842.186 18.8089 327.145 67.6588 
8 0 327.18 31.6529 621.375 460.516 
9 0 1023.24 19.8801 311.719 251.844 
10 0 314.671 38.4886 434.788 161.606 
11 1292.94 1536.16 54.1703 364.885 313.723 
12 2801.52 0 22.6221 383.375 237.51 
13 1022.65 0 42.0554 288.049 326.383 
14 2635.51 241.269 85.7865 523.51 89.9432 
15 0 999.994 23.6528 546.882 105.047 
16 0 2012.37 15.6217 1052.35 156.791 
17 1302.69 0 5.04332 2200.76 122.211 
18 0 3026.95 13.7531 408.841 181.306 
19 0 574.306 22.4919 1825.37 193.253 
20 0 41.4382 29.7032 414.609 224.312 
21 0 491.273 24.0948 890.971 112.506 
22 2443.61 710.592 209.006 1285.14 243.247 
23 0 189.649 97.1401 774.947 529.766 
24 0 0 97.3599 1022.2 447.904 
Total 11498.92 13819.628 1040.9646 14918.99 5009.146 
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4.5 Health Utilities 
      We conducted comprehensive review of the literature to determine appropriate 
quality of life estimates for health states in the Markov models. Available utility data in 
the published literature is very limited. In the base case scenario we assumed that 
brentuximab does not improve quality of life and is same for “Improve or Stable” and 
“FFTF” state. The estimated quality of life for persistent disease is 0.8 after high dose 
chemotherapy plus autologous stem cell transplantation (SCT) [127]. Therefore, in the 
base case, we assumed that utility of “Improve or Stable” and “FFTF” is equal to 0.8. We 
assumed 10% decrease in quality of life when patient relapses after third line treatment 
[127]. Finally, we assumed that patient developing peripheral sensory neuropathy has 
quality of life estimate equal to that of patients developing same adverse reaction with 
metastatic breast cancer [130]. The quality of life of these patients becomes better and 
increases to 0.8 after resolution of adverse the event. We assumed that resolution time of 
the adverse reaction is 13.2 weeks for everyone. Baseline model utility estimates are 
summarized in Table 4-5. 
4.6 Discounting 
     We discounted all future costs and benefits at the rate of 5% as per Canadian 
guidelines[114]. We varied this between 0% and 5% in sensitivity analysis.  
4.7 Sensitivity Analysis 
     We conducted one-way deterministic sensitivity analyses with +/- 20% of the baseline 
value on all of the variables. We also conducted probabilistic sensitivity analyses on key 
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variables to handle uncertainty around the model parameters. The probabilistic sensitivity 
analyses were carried out with 1000 Monte Carlo simulations. We used lognormal 
distribution for cost and beta distribution for probability and utility values respectively. 
The ranges of the variables in the sensitivity analyses and parameters used in 
distributions are summarized in Table 4-5. We also conducted value of the information 
analysis to quantify the cost of uncertainty around baseline ICER. 
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Table 4-5: Model Parameters and Sources 
Variables Base Case Value Duration 
Ranges 
tested in 
Sensitivity 
Probability 
Distribution  
(Parameter) 
Reference 
Cost ($,CAD) 
   Lognormal (µ,σ)  
brentuximab       
    Cost per dose $13,500 
Treatment 
Course $0-$13,500 9.74,0.34 [129] 
    Infusion Time Cost per month¶ $213 
Treatment 
Course +/-20 % 5.35,0.17 LRCP 
    Pharmacy Preparation per 
month¶ $47 
Treatment 
Course +/-20 % 3.76,0.42 LRCP 
    Adverse Reaction¥              $149 One Time         +/-20 %             4.99,0.11 OHIP 
Pre-Progression† (Standard of 
Care) 
     
     Hospitalization Cost 
    CIHI-DAD 
      During First 5 months $1,734 First 5 months +/-20 % 7.46,0.07  
      During following months $149 
Following 
months +/-20 % 4.99,0.12  
      Physician Cost 
    OHIP 
      During First 5 months $825 First 5 months +/-20 % 6.71,0.07  
      During following months $231 
Following 
months +/-20 % 5.43,0.09  
     Drug Cost 
    ODB 
      During First 5 months $116 First 5 months +/-20 % 4.74,0.13  
      During following months $113 
Following  
months +/-20 % 4.72,0.13  
Post-Progression† (Standard of 
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Care) 
     Hospitalization Cost 
    CIHI-DAD 
      During First 5 months $155 First 5 months +/-20 % 5.02,0.2  
      During following months $1,292 
Following  
months +/-20 % 7.16,0.05  
     Physician Cost 
    OHIP 
      During First 5 months $197 First 5 months +/-20 % 5.27,0.14  
      During following months $788 
Following  
months +/-20 % 6.66,0.14  
     Drug Cost 
    ODB 
      During First 5 months $116 First 5 months +/-20 % 4.73, 0.23  
      During following months $233 
Following  
months +/-20 % 5.44,0.16  
Health State Utilities  
   Beta (r, n)§  
     Improve or Stable 0.8 Lifetime 0.6-1 80,100 [127] 
     FFTF 0.8 Lifetime 0.6-1 80,100 [127] 
     Progression -10% Lifetime -5 %-30 % 72,100 [127] 
     Adverse Reaction (AE) ‡     [130] 
         During First 13 Weeks 0.62 13 weeks +/-20 % 62,100  
         During following weeks 0.8 Following weeks +/-20 % 80,100  
     Death 0     
Probabilities 
   Beta (r, n)§  
    Probability of AE 0.0588 Lifetime 0.01-0.2 588 , 10000 [14] 
    FFTF to Death 
 Varying by 
month Lifetime +/-20 %  Varying by month OHIP 
    Progression to Death 
 Varying by 
month Lifetime +/-20 %  Varying by month OHIP 
    FFTF to Progression 
 Varying by 
month Lifetime +/-20 %  Varying by month [14] 
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    Improve or Stable to Progression 
 Varying by 
month Lifetime +/-20 %  Varying by month [14] 
Discount Rate 5%   0%-5%   [114] 
¶  Pharmacist’s labor cost is $35 per cycle, Infusion time cost is $160 per cycle    
† Cost figures include both relevant and other costs for hospitalization and physician costs category    
‡ Peripheral sensory neuropathy is a modeled adverse reaction that stopped treatment continuation   
¥ Cost of consultation visit   
§ Parameters of Beta distribution are integers.   
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Chapter 5  
5  Results 
5.1 Base Case Scenario 
    In the base case scenario brentuximab treatment led to an increase of 0.352 QALYs per 
person and $108,500 per person, which resulted in incremental cost effectiveness ratio 
(ICER) of $308,532 per QALYs gained. 
5.2 Sensitivity Analysis 
5.2.1 Clinical Trial Parameters 
      When the chance of developing peripheral sensory neuropathy dropped to 1% the 
ICER decreased to $259,500 per QALYs gained (Figure 5-1), however ICER was quite 
robust when probability of adverse reaction fall in the range of 0.105 and 0.2. The ICER 
decreased by 2.1% when transition rates from transition rate from “FFTF” to 
“progression” state is increased by 20%. In two way sensitivity analyses we varied the 
probability of serious adverse event over the range of 0.01 and 0.2 and transition rate 
from” improve or stable” to progression by +/-20%. The ICER exceeded the 100,000 per 
QALYs willingness to pay threshold. One way sensitivity analysis on hazard ratio 
showed that ICER falls dramatically to $227,760 per QALY when hazard ratio is 0.1 and 
increases to $384,648 per QALY when brentuximab doesn’t yield additional survival 
benefit to standard of care. 
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Figure 5-2: Threshold analysis on the cost per dose of brentuximab 
      The model was sensitive to most of the utility values in univariate sensitivity 
analyses. ICER dramatically dropped to $231,840 per QALY gained when patients on 
brentuximab treatment had almost perfect health. Conversely, when patients on standard 
of care with no evidence of progression had perfect quality of life, the baseline ICER 
increased to $412,404 per QALY and dropped down to $246,444 per QALY gained when 
patient had utility of 0.6. The change in utility of progression state did not significantly 
impact the ICER outcome. Twenty percent increase in utility of adverse reaction led to an 
ICER of $279,852 per QALYs. The model was sensitive when we varied the discounting 
rate of costs and utilities between 0% and 5%. The ICER dropped to $231,948 per QALY 
when there was no discounting. Model outcomes were quite robust to changes in other 
cost parameters such as cost of brentuximab administration, cost at the pre-progression 
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and post-progression period. In two way sensitivity analyses, ICER fell below $100,000 
per QALYs when probability of adverse reaction and brentuximab cost per dose were 
decreased by 50% and 65% respectively. When drug cost reduces by 60% and quality of 
life of patients on brentuximab treatment converges to perfect health then ICER fell 
below the $100,000 per QALYs gained. 
5.2.3 Probabilistic Sensitivity Analysis 
      In probabilistic sensitivity analyses we simultaneously sampled from distributions 
defined for all key parameters (costs, utilities, probabilities) shown in Table 4-5. The 
scatter plot shows incremental cost versus incremental effectiveness of comparing 
brentuximab to standard of care (Figure 5-3). Sensitivity analyses showed that 100% of 
samples resulted in more cost and more effectiveness, falling in quadrant I and were 
above the 100,000 per QALYs gained willingness to pay threshold line. Approximately 
11% of the samples were below the 200,000 per QALYs willingness to pay threshold 
line.  
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Figure 5-3: Incremental Cost-Effectiveness Scatter Plot 
The simulations showed that brentuximab was not a preferred treatment option using 
willingness to pat threshold  (WTP) of  $100,000 per QALY gained (Figure 5-4). It was 
cost-effective in approximately 11% of simulations at willingness to pay of appoximately 
$200,000 per QALY. Finally brentximab treatment becomes equally preferred at a 
willingess to pay of $290,000 per QALY gained (Figure 5-4).  
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Figure 5-4: Cost Effectiveness Acceptability Curve  
5.2.4 Value of Information 
      Model input parameters contain certain degree of uncertainity. The value of 
information analysis is an analytical framework that determines the monetary value a 
decision maker is willing to pay for conducting additional research to reduce uncertainity 
and hence, support the decision problem [131].  It is based on statistical theory, is the 
difference in expcetation of value under the perfect informaiton and value under the 
current information. In other words, it is the expected cost of uncertainity. 
      Calculation of EVPI is as follows: A probability distribution is defined for each 
model parameter. Using Monte Carlo simulation the model is run many times (e.g.,1000 
times) which will  draw a value from the distribution at each iteration. The expected 
payoff (i.e. net monetary benefit) is calculated across all iterations and the maximum is 
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selected for the baseline decision. For each simulation run, the maximum net monetary 
benefit is calculated for the optimal decision. The difference between the expected 
optimal payoff and the baseline payoff is the expected value of the perfect information.  
We conducted value of information analysis and found that there was no value to 
eliminate probabilistic uncertainity surrounding inputs at the willingness to pay threshold 
of $100,000 per QALY. In other words, it is not worthwhile to undertake additional effort 
to reduce the uncertainity (i.e., more clinical trials) at a WTP threshold of $100,000 per 
QALY gained. 
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Chapter 6  
6  Discussion and Limitations 
6.1 Summary 
     We developed a decision analytic model to investigate cost effectiveness of 
brentuximab versus standard of care for the treatment of HL patients after autologous 
stem cell failure from Canadian healthcare payer perspective. In the base case scenario, 
brentuximab resulted in incremental cost of $108,500 and incremental effect of 0.352 
QALYs with the ICER of $308,532 per QALYs gained. The ICER estimate is much 
higher than 100,000 per QALYs threshold that is graded as having “weak evidence for 
adoption and appropriate utilization” according to published literature in Canada [119].  
     In deterministic sensitivity analysis, the baseline ICER was sensitive to cost of the 
brentuximab, probability of adverse reaction and health utilities. Probabilistic sensitivity 
analysis indicated that brentuximab was not cost effective using willingness to pay of 
100,000 per QALYs gained. Our analysis suggested that minimal survival benefit of 
brentuximab based on current clinical evidence makes it unattractive to healthcare payer 
in Canada. Furthermore, expected value of perfect information (EVPI) analysis showed 
that a healthcare payer would not be willing to pay for further research evidence to 
inform adoption of brentuximab at the current accepted thresholds. 
     The Canadian cost of the drug is not available yet. Therefore, our study plays an 
important role and can aid decision maker with respect to what unit cost per dose 
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represents good value for money. According to Canadian Patented Prices Review Board 
(PMPRB), drug costs in Canada must be at or below a median cost of the drug in 
comparator countries [132]. Using a US costing for brentuximab, we conducted 
preliminary pricing scenarios. We found that price reduction of at least 72% would be 
needed for ICER to be less than $100,000 per QALY.  
6.2 Discussion 
     The survival benefit is a major driver of the ICER. The primary endpoint in the 
brentuximab phase II trial was objective response rate (i.e., tumor shrinkage) that is 
considered as a surrogate endpoint for the survival outcome. The PFS was the secondary 
endpoint in the trial, resulting in modest but statistically superior survival benefit in favor 
of brentuximab. The trial showed median PFS increment of 3.7 months.   
     The drug has entered the US pharmaceutical market upon US FDA approval. In 
Europe, the marketing authorization application (MAA) has been submitted to European 
Medicines Agency. The drug brentuximab has not been approved yet by Health Canada 
for use in Canada. However, like in US, in Canada it is more likely to be granted a 
conditional market approval, as it showed superior toxicity and effectiveness results and 
intends to treat the rare form of cancer where no adequate therapy exists. 
     Other studies have found similarly high cost-effectiveness ratios for targeted therapies. 
For example, economic evaluation of adding bevacizumab to paclitaxel and carboplatin 
for the treatment of ovarian cancer showed that ICER was $479,712 per life years gained 
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[133]. In another study, addition of cetuximab to platinum-based chemotherapy for first-
line treatment of recurrent or metastatic head and neck cancer resulted in $386,000 per 
QALY gained [134]. In general, cancer technologies have resulted in higher ICER 
values, as high as over million dollars per QALY (Table 6-1).  
Table 6-1: League Table for Cancer Treatments 
Intervention  Country ICER  Source 
Endoscopy for Upper GI Screening in general population US $115,664 per QALY [135] 
Adding cetuximab to platinum-based chemotherapy for first-line 
treatment of recurrent or metastatic head and neck cancer 
Canada $386,000 per QALY [134] 
Denosumab versus zoledronic Acid in the management of 
skeletal metastases secondary to breast cancer 
US $697,499 per QALY [136] 
Trastuzumab in combination with chemotherapy for HER2-
positive advanced gastric or gastro esophageal junction cancer China $251,667 per QALY [137] 
Maintenance pemetrexed in patients with advanced 
nonsquamous-cell lung cancer 
Switzerland €106,202 per QALY [138] 
Bevacizumab in combination with paclitaxel in the first-line 
treatment of patients with metastatic breast cancer 
US $745,000 per QALY [139] 
Degarelix for advanced hormone-dependent prostate cancer UK £59,000 per QALY [140] 
Paclitaxel plus carboplatin and bevacizumab US $479,712 per PF-LYS [133] 
Paclitaxel plus carboplatin plus bevacizumab and plus 
bevacizumab maintenance US $401,088 per PF-LYS [133] 
KRAS-testing strategy compared with the no-cetuximab 
strategy for colorectal cancer Japan $160,000 per QALY [141] 
KRAS-testing strategy compared with the no-KRAS-testing 
strategy for colorectal cancer Japan $230,000 per QALY [141] 
Human papillomavirus DNA testing followed by Pap smear for 
cervical cancer screening 
Taiwan $1,247,000 per QALY [142] 
Annual screening for renal cancer in recipients of kidney 
transplants Australia $320,988 per LYS [143] 
Addition of cetuximab to first-line chemotherapy in patients 
with advanced non-small-cell lung cancer 
Switzerland €376,205 per QALY [144] 
Sunitinib for first-line treatment of metastatic renal cell 
carcinoma Canada $144K per QALY [145] 
Cetuximab for the treatment of recurrent and/or metastatic 
squamous cell carcinoma of the head and neck 
UK £121367 per QALY [146] 
Lapatinib in HER-2-positive advanced breast cancer US $166,113 per QALY [147] 
Initial HercepTest with fluorescence in situ hybridization 
(FISH) confirmation for metastatic breast cancer US $125,000 per QALY [148] 
Aspirin chemoprevention plus colonoscopy screening 
concomitantly for colorectal cancer 
US $227,607 per LYS [149] 
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       In Canada, a cost effectiveness analysis is required for the drug reimbursement 
decisions. The oncology drugs are reviewed by a different body than non-oncology drugs. 
In 2007, an interim, cross-provincial Joint Oncology Drug Review (JODR) process was 
established for reviewing oncology drugs. As a part of JODR process, Committee to 
Evaluate Drugs (CED) and Cancer Care Ontario (CCO) assessed the cancer drugs and 
provided recommendation to provincial public funding agencies (except Quebec). Since 
2010, a pan-Canadian Oncology Drug Review (pCODR) evaluates manufacturer’s drug 
submissions for drug formulary listing and makes drug funding decisions to guide 
provincial healthcare payers. 
      There is no published implicit threshold in Canada however, in general anti-cancer 
drugs are approved at higher acceptable thresholds than other medications [145, 150]. 
The Table 6-2 summarizes funding recommendations and corresponding ICER values for 
the some of the recently evaluated oncology drugs which can be recommended for “list”, 
“not list” or “listing with condition” on the formulary. Based upon past experience, the 
drugs with more overall clinical benefit and effective over standard treatment options 
might be approved at the higher ICER, conditioned on the cost-effectiveness to be 
improved to the WTP level of the jurisdictions. 
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Table 6-2: ICER Results versus Reimbursement Recommendation 
Drug  
Recommendati
on Indication ICER Source 
Sunitinib (Sutent) List with condition First-line metastatic 
renal cell carcinoma 
$144K/QALY [145] 
Sunitinib (Sutent) Do not list Second-line metastatic 
renal cell carcinoma 
$56K/QALY [145] 
Sunitinib (Sutent) List with condition Gastrointestinal stromal 
tumor 
$80K/QALY [145] 
Sorafenib (Nexavar) Do not list Second-line metastatic 
renal cell carcinoma 
$36/LYG [145] 
Pazopanib hydrochloride (Votrient)  List with condition advanced or metastatic 
clear cell renal 
carcinoma 
$57,309/QALY [151] 
Ipilimumab (Yervoy) List with condition Treatment of advanced 
melanoma 
(unresectable Stage III 
and IV melanoma) in 
patients who have 
received prior systemic 
therapy 
$269,299/QALY [151] 
Sunitinib malate (Sutent) List with condition Patients with 
unresectable locally 
advanced or metastatic, 
well-differentiated 
pancreatic 
neuroendocrine 
tumours, whose disease 
is progressive. 
$204,559-$268,055/QALY [151] 
Vemurafenib (Zelboraf) List with condition Treatment of BRAF 
V600 mutation-positive 
unresectable or 
metastatic melanoma 
$221,668-$275,707/QALY  [151] 
      Because fast track approval is based on the surrogate clinical outcome, regulatory 
bodies require confirmatory post-marketing randomized studies to be conducted in order 
to confirm efficacy and safety for drugs being approved through an accelerated approval 
process. However, post marketing studies may take many years especially for orphan 
drugs, based on past experience. Waiting for the phase III survival data to conduct cost- 
effectiveness may not be practical from payer’s perspective. Health care payers have to 
make a quick decision regarding funding upon market approval. Hence, we think the 
cost-effectiveness of the drug must be considered at earlier stages and the results must be 
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updated as new data become available. A confirmatory randomized control phase III trial 
testing survival benefit of the brentuximab is already underway. 
     Use of administrative databases might have missing data and misclassification 
challenges to some extent. The validity of the administrative databases of Ontario has 
been evaluated by several studies. The validity of OHIP database was assessed to 
ascertain the influenza vaccination status and patients with hypertension [152, 153]. 
OHIP had a moderate agreement (i.e., kappa statistics), higher specificity and fair 
sensitivity. The validity of OCR has been tested with respect to cause of death of breast 
cancer patients [154]. OCR had high level agreement, higher sensitivity and specificity. 
Similarly, the validation study of Institute for Clinical Evaluative Sciences (ICES) 
showed higher agreement in diagnostics, demographics and interventions data in CIHI-
DAD database [155]. 
6.3  “Early Look” Model  
      The use of economic evaluation at early stages has been suggested by several studies 
[156, 157]. Despite some challenges, early economic assessment has gained popularity in 
the past few years [158]. It has several limitations to overcome; however, these models 
are worthwhile, yielding interesting results to pharmaceutical industry, the hematology 
community, health care payers and to society as a whole.   
       Early look models have several advantages. First, early economic assessment 
determines the potentially successful products which inform strategic research and 
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“go/no-go” development decisions [159]. Using preliminary data from phase II trial to 
build decision analytical model helps to predict the market potential and hence, economic 
viability of the drug before phase III trial, which is the most resource intensive stage. 
Second, early economic evaluation may change study design and protocols of the further 
clinical trials [159]. For example, early look economic models can determine the crucial 
sensitive variables which in turn can aid the data collection decisions. Our model showed 
that ICER was sensitive to quality of life of patients receiving the brentuximab treatment. 
Thus, quality of life assessment in phase III brentuximab trial would be very crucial. 
Finally, “early look” models help to conduct preliminary cost effectiveness at different 
pricing scenarios which identifies the optimal price at which the drug is cost-effective or 
below the willingness to pay (WTP) of the payer. 
        There are several challenges of using “early look” economic models. The available 
data are scarce and has considerable uncertainty due to lower sample size. Moreover, the 
clinical evidence data may be based on open label, single arm and non-randomized trial 
that may not produce definitive results. Because early data are very limited, data from 
literature or expert opinion are used to parameterize the model that might affect economic 
outcomes. Finally, using surrogate endpoints and short follow up times from early 
clinical trials have inherent limitations [160]. 
6.4 Limitations 
      We recognize some limitations of this study. First, we acknowledge that phase II 
results should be interpreted carefully. The PFS outcomes are based on intra-patient sub-
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group analysis on 57 patients which may not reflect the treatment effect in a broad 
population in randomized setting. However, uncertainty around the progression rates was 
accounted for in probabilistic sensitivity analysis. Our definition of progression endpoint 
is a proxy measure and it is based on treatment switch which may not necessarily reflect 
the actual relapse. In practice, the progression is verified by diagnostic procedures such 
as CT and PET scans and biopsy before the actual treatment start.  Second, our definition 
of progression does not capture the change in chemotherapy regimen since the same 
billing code may refer to more than one chemotherapy regimen. Third, OHIP service 
codes for chemotherapy do not specify the chemotherapy type, name or dose and hence, 
the cost of the chemotherapy dose is not included in analysis. Finally, there may be 
uncertainty around the baseline utility values which were mitigated in sensitivity analysis.       
6.5 Strengths 
      To our knowledge, our analysis is the first economic analyses of brentuximab at early 
stage and is the first comprehensive decision analytic model developed to simulate the 
course of HL disease and treatment alternatives. The costs and transition probabilities of 
model were estimated using Canadian administrative databases. The use of population 
based registry and administrative databases to conduct cost analysis has gained popularity 
in recent years. There have been several studies from Canada using OHIP physician 
billing codes to define a stage of the cancer [161, 162]. However, this analysis is the first 
attempt to define progression using treatment records of OHIP database. In conclusion, 
our study may play an important role and will inform drug reimbursement decisions by 
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provincial funding agencies and give an idea on potential budget impact before it gets 
regulatory and reimbursement approval. 
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Chapter 7  
7 Conclusion 
    We conducted cost-effectiveness analysis of brentuximab using data from phase II 
clinical trial and Canadian administrative databases. In the base case scenario ICER was 
$308,532 per QALYs gained. The baseline ICER was significantly higher than $100,000 
per QALY threshold and does not represent good value for money based upon current 
accepted willingness to pay thresholds.  The baseline ICER was sensitive to cost of the 
brentuximab, probability of adverse reaction, health related quality of life estimates. 
EVPI analyses showed that decision maker is not willing to pay to eliminate all 
uncertainty at the willingness to pay of $100,000 per QALY gained. This early stage 
economic evaluation will guide the decision makers in the light of available information. 
Model inputs should be refined and updated as new data become available.  
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